Cell Therapy

Developed for: diastolic heart failure
Investigated by: University Medical Centre Ljubljana

Trials 1

today NCT02923609 · Ph 2

201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT02923609	Jan 2016 → Jan 2022	diastolic heart failure	University Medical Centre Ljubljana	Completed	Met primary

News releases announcing trial results or a regulatory action · 164

Date	Issuer	Release
2026-07-13	Longeveron Inc.	Results Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease longeveron.com ↗ Results support a clinically relevant and long-lasting anti-inflammatory mechanism of action of laromestrocel in gray and white matter of the brain, indicate potential blood biomarker correlates with clinical outcomes, and support continued clinical development of laromestrocel for Alzheimer’s disease
2026-07-01	Vertex Pharmaceuticals Incorporated	Regulatory Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia vrtx.com ↗ Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT).
2026-06-09	Imviva Bio	Regulatory ImvivaBio Receives FDA Investigational New Drug Approval for CTA313, a Dual-Targeted CD19/BCMA Allogeneic CAR-T Cell Therapy for Autoimmune Diseases imvivabio.com ↗ The FDA cleared Phase 1b basket design will evaluate the safety, efficacy, and cellular pharmacokinetics of CTA313 across multiple B-cell-mediated autoimmune conditions, including systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitis.
2026-06-01	In8bio Inc.	Results IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026 in8bio.com ↗ Among patients who received up to six repeat doses of genetically modified gamma delta (γδ) T cells (DeltEx DRI), median progression-free survival (mPFS) reached 13.0 months, nearly double the 6.6 months observed in patients receiving standard-of-care (SOC) alone.
2026-05-22	AstraZeneca	Results AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026 astrazeneca.com ↗ Initial phase 1 study results of NT-175 engineered T-cell therapy in TP53 R175H–mutated unresectable advanced solid tumors.
2026-05-19	Second Life Therapeutics	Results Second Life Therapeutics Presents SL-28 Complete Response Case Report at the American Thoracic Society 2026 International Conference secondlifetherapeutics.com ↗ Novel off-the-shelf cell therapy SL-28 was associated with complete response in a patient with malignant pleural effusion under compassionate use.
2026-05-14	In8bio Inc.	Results IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma in8bio.com ↗ Multidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and correlates with improved survival outcomes in glioblastoma
2026-05-12	MiNK Therapeutics	Results MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 minktherapeutics.com ↗ iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS — from the same manufacturing donor batch, without genetic engineering
2026-05-12	Caring Cross	Results Caring Cross Announces Promising Clinical Data with Single-Dose anti-HIV CAR-T Cell Therapy caringcross.org ↗ Today, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Boston, Massachusetts, Caring Cross announced early clinical data from a first-in-human Phase I/IIa trial of a novel CAR-T cell strategy in people living with HIV.
2026-03-10	ExCellThera inc.	Results Zemcelpro® (dorocubicel) positive results in high- and very high-risk blood cancers to be reported at the EBMT 2026 Annual Meeting excellthera.com ↗ At 24 months post-transplant, overall survival (OS), progression-free survival (PFS) and relapse-free survival (RFS) were 63.7%, 57.0% and 60%, respectively, among Zemcelpro® (dorocubicel)-treated patients.
2026-02-16	ExCellThera inc.	Regulatory Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany excellthera.com ↗ ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, and its wholly owned subsidiary Cordex Biologics (Cordex), announced that Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy, has been granted Status 1 listing by the NUB (Neue Untersuchungs- und Behandlungsmethoden) program in Germany.
2026-02-09	Estrella Biopharma, Inc.	Results Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR® estrellabio.com ↗ The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS ® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL).
2026-02-05	Iovance Biotherapeutics, Inc.	Results Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma iovance.com ↗ The physician-assessed confirmed objective response rate (ORR) was 44% (18/41) and the disease control rate was 73% (30/41).
2026-01-23	Ossium Health, Inc.	Results Ossium Health to Present New Clinical Data from PRESERVE I Study at the 2026 Tandem Meetings ossiumhealth.com ↗ Ossium’s Chief Medical Officer, Dr. Sagar Munjal, will present the study’s encouraging preliminary data, which demonstrate the safety and feasibility of transplanting bone marrow derived from deceased donors.
2026-01-01	CellPraxis Bioengenharia Ltda.	Results ReACT e Angina Refratária: quando a terapia celular abre caminho para pacientes 'sem opção' cellpraxis.com.br ↗ O protocolo ReACT (Refractory Angina Cell Therapy), desenvolvido no ecossistema Cryopraxis/CellPraxis e testado em pacientes com angina refratária sem disfunção ventricular esquerda, apresentou melhora clínica progressiva e sustentada e redução objetiva de isquemia miocárdica em um estudo fase I/IIa (aberto e não controlado) publicado em 2009.
2025-12-19	ExCellThera inc.	Results Zemcelpro® (UM171 Cell Therapy) improved outcomes compared with common graft sources: European real-world evidence excellthera.com ↗ ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, and its wholly owned subsidiary Cordex Biologics, announced the publication in the journal Transplantation and Cell Therapy of results from a retrospective effectiveness analysis comparing outcomes of adult patients with blood cancers who received Zemcelpro® (UM171 Cell Therapy) with those treated with conventional allogeneic hematopoietic stem cell transplants.
2025-12-08	Senti Biosciences	Results Promising results from an ongoing Phase I multicenter study of SENTI-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) sentibio.com ↗ Here we present clinical data from 20 R/R AML patients, including 14 at RP2D and 6 at Dose Level 1
2025-12-08	Senti Biosciences	Results Correlative data from an ongoing Phase 1, multicenter study of SENTI-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action sentibio.com ↗ Substantial AML blast reduction was observed in 50% of patients.
2025-12-08	Bristol-Myers Squibb	Results Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025 bms.com ↗ Highlights include updates from the company’s targeted protein degradation pipeline, including data on first-in-class investigational lymphoma CELMoD ™ agent golcadomide and first-in-class BCL6 ligand-directed degrader BMS-986458; alongside long-term results for Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, from the Phase 3 TRANSFORM and Phase 2 TRANSCEND FL trials.
2025-12-08	Imviva Bio	Results Validating Data for CAR-T Cell Therapies CTD402 and CTA311 in Five Presentations at the 67th American Society of Hematology Annual Meeting imvivabio.com ↗ The first poster ( Abstract #5954 ) highlighted the promising ‘off-the-shelf' CAR-T approach of CTD402, being evaluated in the Phase 1b/2 TENACITY-01 clinical trial ( NCT07070219 ) for the treatment of R/R T-ALL and LBL.
2025-12-08	Imviva Bio	Results ImvivaBio Presents Validating Data for CAR-T Cell Therapies CTD402 and CTA311 in Five Presentations at the 67th American Society of Hematology Annual Meeting imvivabio.com ↗ Preliminary data from earlier studies suggest CTD402 achieves high MRD-negative remission rates and durable responses, supporting its potential as a transformative therapy for R/R T-ALL/LBL.
2025-12-08	Imviva Bio	Results ImvivaBio Presents Clinical Breakthroughs for CTD402 in High-Mortality T-Cell and Myeloid Leukemias at the 67th American Society of Hematology Annual Meeting imvivabio.com ↗ ImvivaBio, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today presented clinical data for CTD402, its investigational allogeneic anti-CD7 CAR-T cell therapy, in two oral sessions at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
2025-12-08	Imviva Bio	Results Clinical Breakthroughs for CTD402 in High-Mortality T-Cell and Myeloid Leukemias presented at the 67th American Society of Hematology Annual Meeting imvivabio.com ↗ Safety was consistent with T-ALL/LBL observations, with manageable cytokine release syndrome and no dose-limiting toxicities or treatment-related deaths, and cytopenia resolved in most responders.
2025-12-05	Gamida Cell ltd	Regulatory FDA approves Omisirge® as First Approved Cell Therapy to Treat Severe Aplastic Anemia gamida-cell.com ↗
2025-12-04	AstraZeneca	Results AstraZeneca advances haematology and cell therapy ambition with largest-ever presence at ASH astrazeneca.com ↗ Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary results from the DURGA-1 Phase 1b/2 study
2025-12-01	Longeveron Inc.	Results Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) longeveron.com ↗ Results obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel was associated with a reduction in MRI measured neuroinflammation compared to placebo across multiple key brain regions, including key Alzheimer’s disease-associated regions, most notably in the hippocampus
2025-11-03	CARsgen Therapeutics Co., Ltd.	Results CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B carsgen.com ↗ The data showed that both allogeneic CAR-T products demonstrated initially favorable safety profiles and encouraging efficacy signals.
2025-10-30	Second Life Therapeutics	Results Regulating white blood cell activity through the novel universal receptive system secondlifetherapeutics.com ↗ Second Life Therapeutics announced the publication of a case report abstract in the American Journal of Respiratory and Critical Care Medicine supplement describing a complete response in a patient with stage IV non-small cell lung cancer and malignant pleural effusion treated with SL-28, the company’s investigational allogeneic cell therapy.
2025-10-08	CARsgen Therapeutics Co., Ltd.	Results CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology carsgen.com ↗ With a median follow-up of 10.71 months (IQR 6.13-12.02), the objective response rate (ORR) was 100% (95%CI, 83.2-100).
2025-10-07	Adicet Therapeutics	Results Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) adicetbio.com ↗ As of the August 31, 2025 data cut-off date, all five LN patients experienced improved renal function, including three complete renal responses and Definition Of Remission In Systemic lupus erythematosus (DORIS) remissions, and two partial renal responses, with all responses ongoing
2025-10-02	jCyte, Inc	Results Intravitreal Injection of Retinal Progenitor Cells Shows Promise in Preclinical Study for Diabetic Retinopathy jcyte.com ↗ Key findings include: Improved Retinal Function – Rat RPC-treated eyes demonstrated stronger ERG responses (b-wave and oscillatory potentials), along with enhanced optomotor response and contrast sensitivity compared to controls.
2025-08-28	Hemostemix	Results Hemostemix’s 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease hemostemix.com ↗ “The results of these three studies significantly derisk a phase II randomized clinical trial,” stated Thomas Smeenk.
2025-08-27	ExCellThera inc.	Regulatory Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells excellthera.com ↗ Zemcelpro® is conditionally authorized by the European Commission for adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is available
2025-07-08	Longeveron Inc.	Regulatory Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) longeveron.com ↗ Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its stem cell therapy laromestrocel as a potential treatment for pediatric dilated cardiomyopathy (DCM).
2025-06-25	Imviva Bio	Results Latest Clinical Data on Universal CAR-T Therapy CTD402 for Patients with R/R T-ALL/LBL presented at EHA 2025 imvivabio.com ↗ At this event, Bioheng Therapeutics presented the latest clinical data on its universal CAR-T product, CTD402, for the treatment of patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), in the form of an oral report.
2025-06-24	Adocia	Results ADOCIA Presentations at ADA & IPITA Scientific Conferences Highlight Scalability and Good Translation of AdoShell® from Human Islets to Stem Cell-Derived Islets adocia.com ↗ Finally, AdoShell® enables long-term function and efficacy of SCDI in mice for at least 24 weeks.
2025-06-19	ExCellThera inc.	Regulatory Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells excellthera.com ↗
2025-06-01	Allogene Therapeutics	Results Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO allogene.com ↗ A Single Dose of ALLO-316 Achieved a 31% Confirmed Response Rate
2025-05-22	Janssen Research & Development, LLC	Results Johnson & Johnson showcases latest advancements in cancer innovation with more than 70 clinical and real-world studies at ASCO and EHA jnj.com ↗ First results from a global Phase 1b study evaluatingJNJ-90014496, a CD19/CD20 bispecific CAR-T cell therapy, in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL)
2025-04-29	Senti Biosciences	Results First-In-Human, Multicenter Study of SENTI-202, a CD33/FLT3 Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy in Hematologic Malignancies including AML: Correlative Data sentibio.com ↗ AML blast reduction (measured locally by flow cytometry) was noted in a majority of subjects across all dosing cohorts.
2025-04-27	Senti Biosciences	Results First-In-Human, Multicenter Study of SENTI-202, a CD33/FLT3 Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy in Hematologic Malignancies including AML: Clinical Data sentibio.com ↗ Identified as preliminary RP2D based on totality of clinical data
2025-01-22	Agenus Inc.	Results Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease agenusbio.com ↗
2024-12-09	Synthekine	Results Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting synthekine.com ↗ This regimen also demonstrated durable responses, including complete responses in all 4 patients with non-Hodgkin lymphoma (NHL).
2024-12-09	Bristol-Myers Squibb	Results Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline bms.com ↗ Bristol Myers Squibb (NYSE: BMY) announced results from 18 presentations reinforcing its leadership in cell therapy, with data demonstrating efficacy, durability and safety of currently available therapies in blood cancers and highlighting the potential of its pipeline for future indications including autoimmune diseases.
2024-11-19	Bristol-Myers Squibb	Results Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms bms.com ↗ Data from more than 20 programs, including new research from cell therapy and targeted protein degradation platforms, showcase the depth and breadth of BMS’ diverse portfolio and ongoing leadership in blood diseases and beyond
2024-11-07	AstraZeneca	Results AstraZeneca showcases strength of haematology portfolio and pipeline at ASH 2024 astrazeneca.com ↗ Preliminary results from the ongoing investigator-initiated trial of AZD0120 suggest deep responses and an acceptable safety profile, with no ICANS and no ≥Grade 2 CRS events observed in this patient population.
2024-10-29	Longeveron Inc.	Results Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) longeveron.com ↗ This data adds to the positive clinical information from the Phase 2a CLEAR MIND clinical trial that showed Lomecel-B™ improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s disease.
2024-10-27	Longeveron Inc.	Results Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting longeveron.com ↗ HLHS is a devastating disease for patients and their families, so I am impressed and very encouraged to see the continued long-term survival of patients treated with Lomecel-B TM in the ELPIS I study,
2024-10-24	PolTREG S.A.	Regulatory PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes poltreg.bio ↗ Recruitment will go ahead after European Medicines Agency approval
2024-10-17	Nektar Therapeutics	Results Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia nektar.com ↗ Compared to Stanford's control group previously treated with the CD19-22 CAR-T cell therapy, NKTR-255 when added to the cell therapy increased the 12-month relapse free survival from 38% to 67%.
2024-10-15	Tevogen Bio Inc	Results Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use tevogen.com ↗ Patients in the treatment group had symptom improvement and resolution more consistently, and in many cases, faster, than those in the observation group.
2024-09-23	Immusoft of CA, Inc.	Results Immusoft to Announce Positive Phase 1 Data for First Engineered B Cell Therapy in a Clinical Trial immusoft.com ↗ SAN FRANCISCO – September 23, 2024 – Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation (“Immusoft”), a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced positive results from the Phase 1 ISP-001 trial evaluating the therapy in a patient with mucopolysaccharidosis type I (MPS I).
2024-09-09	PolTREG S.A.	Results PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence poltreg.bio ↗
2024-08-07	PeproMene Bio, Inc.	Results PeproMene Bio announced study demonstrating strong polyfunctionality of novel chimeric antigen receptor (CAR) T cells pepromenebio.com ↗ The study reported robust indicators of polyfunctionality, which correlated with successful CAR T cell expansion post-infusion and the patient’s ongoing remission.
2024-07-28	Longeveron Inc.	Results Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC) longeveron.com ↗ Featured Research Session oral presentation highlights findings that show Lomecel-B™ improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s Disease
2024-07-17	Longeveron Inc.	Regulatory Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease longeveron.com ↗ today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lomecel-B™ for the treatment of mild Alzheimer’s Disease .
2024-07-10	Longeveron Inc.	Regulatory Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease longeveron.com ↗ today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lomecel-B™ for the treatment of mild Alzheimer’s Disease .
2024-06-25	FibroBiologics	Results FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology fibrobiologics.com ↗ The organoid, composed of fibroblasts and thymus derived cells, is capable of generating mature and diverse T cells, including CD4, CD8, and regulatory T cells, in vitro and in vivo.
2024-06-23	Kadimastem	Results The World Prestigious Diabetes Research Institute, University of Miami, Announces Kadimastem kadimastem.com ↗ Kadimastem Ltd. (TASE: KDST), June 23rd, 2024, announces positive results of its leading diabetes product jointly developed with iTolerance Inc.
2024-06-18	Adocia	Results ADOCIA Announces Three Presentations at the American Diabetes Association 84th Scientific Sessions adocia.com ↗
2024-06-15	CARsgen Therapeutics Co., Ltd.	Results CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024 carsgen.com ↗ The overall response rate was 90%, including 5 patients (50%) with stringent complete response (sCR), 2 patients (20%) with very good partial response (VGPR), and 2 patients (20%) with partial response (PR).
2024-06-04	ExCellThera inc.	Regulatory ExCellThera Announces International Non-proprietary Name and New Orphan Drug Designation for UM171 Cell Therapy excellthera.com ↗
2024-06-03	Kite, A Gilead Company	Results Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia kitepharma.com ↗ Kite, a Gilead Company (Nasdaq: GILD), today announced updated, four-year overall survival (OS) data from the pivotal ZUMA-3 study evaluating the CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
2024-05-23	Bristol-Myers Squibb	Results Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms bms.com ↗ First results from the Phase 1 study of GPRC5D-directed CAR T cell therapy (BMS-986393/CC-95266) showcasing promising preliminary efficacy and safety outcomes with a single infusion of BMS-986393
2024-05-15	Senti Biosciences	Results Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits sentibio.com ↗
2024-05-02	Quell Therapeutics Limited	Results Quell Therapeutics Highlights Clinical Potential of QEL-001 and its Multi-Modular Treg Cell Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting quell-tx.com ↗ These data provide a rigorous scientific foundation for our engineered Treg cell therapy approach and we are delighted that these desired characteristics are beginning to be validated clinically through initial findings with QEL-001 in our ongoing Phase 1/2 LIBERATE trial.
2024-04-11	Orca Biosystems, Inc.	Results Orca Bio to Present Positive Clinical Data on Orca-T at the 50th Annual Meeting of the EBMT orcabio.com ↗ Preliminary data with Orca-T and RIC in patients with hematologic malignancies showed encouraging rates of relapse-free survival (77%).
2024-02-26	TScan Therapeutics, Inc.	Results TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR tscan.com ↗ We are encouraged to see that all eight patients treated with our cell therapy products achieved and maintained complete donor chimerism at every time-point, with four of these patients past the 10-month mark.
2024-02-07	Throne Biotechnologies Inc.	Results New Pre-Clinical Studies Demonstrate Cord Blood Stem Cells (CB-SC) Ameliorate the Graft-vs-Host Disease (GvHD) Involved in the Allogeneic Hematopoietic Stem Cell Transplantation thronebio.com ↗ Animal studies demonstrated that CB-SC ameliorated the development of GvHD responses in a xenogeneic human peripheral blood mononuclear cells (PBMC)-induced NSG mouse model.
2024-01-23	PeproMene Bio, Inc.	Results PeproMene Bio, Inc. Announces Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) in the Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope pepromenebio.com ↗ PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the cohort 1 first patient treated in its Phase 1 relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) clinical trial of PMB-CT01 (BAFFR-CAR T Cells) has reached complete remission at one-month post treatment.
2024-01-16	Vertex Pharmaceuticals Incorporated	Regulatory Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia vrtx.com ↗
2024-01-16	CRISPR Therapeutics	Regulatory CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia crisprtx.com ↗ CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older.
2024-01-01	Hopstem Biotechnology Inc.	Results 2023【十二月精选】领域最新进展 hopstem.com ↗ 初步的研究数据表明，C-CAR031在晚期肝细胞癌患者中显示出良好的抗肿瘤活性和药代动力学特征。
2023-12-12	ExCellThera inc.	Results ExCellThera Announces Positive Phase 2 Study Results from UM171 Cell Therapy in Patients with High-risk Leukemias and Myelodysplasias at American Society of Hematology (ASH) 2023 Annual Meeting excellthera.com ↗ UM171 cell therapy achieved the primary endpoint of progression-free survival (63% at 2 years) in high and very high-risk cohort and demonstrated an excellent safety profile
2023-12-11	Gilead Sciences	Results New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers gilead.com ↗ Kite, a Gilead Company (Nasdaq: GILD), today announced the results of four new analyses supporting the use of Tecartus ® (brexucabtagene autoleucel) in relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory adult B-cell precursor acute lymphoblastic leukemia (R/R B-ALL).
2023-12-11	Bristol-Myers Squibb	Results Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs bms.com ↗ Updated data from the Phase 1 study of CAR T BMS-986393, a potential first-in-class cell therapy targeting GPRC5D, show deepening responses, a tolerable safety profile, and activity across both B-cell maturation antigen (BCMA)-naïve and -exposed patients
2023-11-15	Kyverna Therapeutics	Results Kyverna Therapeutics Announces Publication in The Lancet Neurology of Case Report of Patient with Refractory Myasthenia Gravis Treated with Investigational KYV-101 kyvernatx.com ↗ Within the 2-month post-treatment follow-up period, the patient was not observed to experience any adverse events related to chimeric antigen receptor (CAR) T-cell therapy, such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
2023-11-09	Adocia	Results ADOCIA Revealed Promising Preclinical Data on AdoShell® Islets for Cell Therapy of Diabetes adocia.com ↗ Human islets encapsulated in AdoShell ® scaffold maintain, in vitro , a gluco -responsive insulin secretion comparable to naked islets .
2023-09-18	Kite, A Gilead Company	Results Kite’s CAR T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma kitepharma.com ↗ The study met its primary endpoint, with a complete metabolic response (CMR) of 71% (n=44, 95% confidence interval [CI], 58.1%–81.8%) at 3 months versus 12% expected with standard of care (based on historical controls).
2023-09-18	Gilead Sciences	Results Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma gilead.com ↗ The study met its primary endpoint, with a complete metabolic response (CMR) of 71% (n=44, 95% confidence interval [CI], 58.1%–81.8%) at 3 months versus 12% expected with standard of care (based on historical controls).
2023-08-28	Bayer	Results BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint bayer.com ↗ Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year.
2023-06-10	Nkarta, Inc.	Results Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma nkartatx.com ↗ 7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose in the Phase 1 dose escalation study
2023-06-08	Cellectis S.A.	Results Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023 cellectis.com ↗ The data presented support the preliminary safety and efficacy of UCART22 in a heavily pretreated relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) population.
2023-06-05	Janssen Research & Development, LLC	Results CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study jnj.com ↗ results from the Phase 3 CARTITUDE-4 study showed CARVYKTI®(ciltacabtagene autoleucel; cilta-cel) reduced the risk of disease progression or death by 74 percent compared to two standard of care treatment (SOC) regimens
2023-05-17	TScan Therapeutics, Inc.	Results TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting tscan.com ↗ Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation
2023-05-09	Adaptive Biotechnologies	Regulatory Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology adaptivebiotech.com ↗ This is the first TCR-based therapeutic product candidate to advance into clinical development based on Adaptive’s collaboration with Genentech in oncology.
2023-05-03	Bristol-Myers Squibb	Regulatory Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy bms.com ↗ This approval covers all European Union (EU) member states.
2023-04-10	OBI Pharma, Inc	Results OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy obipharma.com ↗ OBI has also developed the first CAR T-cell therapy (OBI-R007) targeting Globo H, which demonstrates a strong and specific anti-tumor effect on Globo H-expressing tumor cells.
2023-02-09	Kite, A Gilead Company	Results Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia kitepharma.com ↗ Kite, a Gilead Company (Nasdaq: GILD), today announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus® (brexucabtagene autoleucel).
2023-02-09	Gilead Sciences	Results Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia gilead.com ↗ Kite, a Gilead Company (Nasdaq: GILD), today announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus ® (brexucabtagene autoleucel).
2022-12-20	PeproMene Bio, Inc.	Results PeproMene Bio, Inc. Announced Complete Response of The First Patient Treated in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope pepromenebio.com ↗ We are pleased to see a deep complete remission which is minimal residual disease negative,
2022-12-11	Kite, A Gilead Company	Results Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis kitepharma.com ↗ The analysis reported shorter vein-to-vein times associated with improved outcomes in patients treated with Yescarta, adjusted for key prognostic factors.
2022-12-11	Gilead Sciences	Results Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis gilead.com ↗ The analysis reported shorter vein-to-vein times associated with improved outcomes in patients treated with Yescarta, adjusted for key prognostic factors.
2022-09-07	Adocia	Results ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes adocia.com ↗
2022-08-10	Bristol-Myers Squibb	Results Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma bms.com ↗
2022-06-28	Kite, A Gilead Company	Regulatory Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma kitepharma.com ↗ Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Commission (EC) has approved its CAR T-cell therapy Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.
2022-06-28	Gilead Sciences	Regulatory Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma gilead.com ↗
2022-06-15	NeoImmuneTech	Results A Study in Nature Communications Reports that NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity neoimmunetech.com ↗ NT-I7 enhanced the efficacy of CAR-T therapy against acute myeloid leukemia and B cell lymphoma, significantly prolonging survival in murine models.
2022-06-11	CRISPR Therapeutics	Results CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress crisprtx.com ↗
2022-06-06	Adicet Therapeutics	Results Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting adicetbio.com ↗ When we look at the totality of these early data, we have an indicator that allogeneic gamma-delta CAR T cell therapy like ADI-001 could be a significant advance.
2022-05-19	TScan Therapeutics, Inc.	Results TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting tscan.com ↗ We are excited to report initial preclinical results, which showed strong cytoxicity of TSC-200-A02 in HPV+ target cell lines and no off-target activity.
2022-05-19	Mustang Bio, Inc.	Results Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107 mustangbio.com ↗ The treatment was well tolerated, and all patients experienced complete hematopoietic recovery.
2022-05-12	AstraZeneca	Results Human ventricular progenitor cells promote the formation of new heart tissue following a heart attack astrazeneca.com ↗ An investigational study of a new cell therapy approach for heart failure has demonstrated human ventricular progenitor (HVP) cells are able to promote the regeneration of healthy cardiac tissue following a heart attack, improve cardiac function and reduce scar tissue.
2022-04-23	Nektar Therapeutics	Results Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings \| Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® nektar.com ↗ My lab's findings show that NKTR-255's ability to expand and proliferate NK cells resulted in the enhancement of the efficacy of two different CAR therapies in our preclinical models.
2022-04-13	Mustang Bio, Inc.	Results Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma mustangbio.com ↗
2022-04-12	BriaCell Therapeutics Corporation	Results BriaCell Presents Development Details of Bria-OTS(TM) Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022 briacell.com ↗ BriaCell’s lead candidate, the Bria-IMT™ regimen, has produced a safe and effective immune response and disease control in heavily pre-treated advanced breast cancer patients.
2022-04-11	BioNTech SE	Results BioNTech Presents Positive Preliminary Phase 1/2 Data for First-in-Class CAR-T Program BNT211 at AACR biontech.com ↗ The preliminary results demonstrated an encouraging safety profile and anti-tumor activity in testicular cancer patients at the first evaluated dose levels of BNT211.
2022-04-08	Gracell Biotechnologies (Shanghai) Co., Ltd.	Results Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL gracellbio.com ↗ Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-ALL
2022-04-08	BlueSphere Bio, Inc	Results BlueSphere Bio Presents New Data Supporting the Potential of its TCXpress™ Platform at the 2022 AACR Meeting bluespherebio.com ↗
2022-01-06	Bayer	Results BlueRock Therapeutics Announces Closeout of First Cohort in Phase 1 Trial in Patients with Advanced Parkinson’s Disease bayer.com ↗ No severe adverse events were observed in any participating patients.
2021-12-13	Kite, A Gilead Company	Results Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma kitepharma.com ↗ After a single infusion of Yescarta, 89% of evaluable patients achieved a response (ORR) (n=37 evaluable for efficacy), including 78% of patients with a complete response (CR) at a median follow-up of 15.9 months.
2021-12-13	Gilead Sciences	Results Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma gilead.com ↗
2021-12-11	Orca Biosystems, Inc.	Results Positive Clinical Results from More than 100 Patients Treated with Orca Bio’s Lead Investigational High Precision Cell Therapy Presented at 63rd ASH Annual Meeting orcabio.com ↗ The new data on Orca Bio’s lead investigational high-precision cell therapy, Orca-T, include updated results from 137 patients with hematologic malignancies, which continued to show an increase in overall survival rates and a reduction of acute and chronic graft versus host disease (GvHD) compared to standard of care
2021-12-10	Caring Cross	Results Caring Cross Announces Publication in Nature Communications Demonstrating Effectiveness of Place-of-Care Manufacture of Anti-CD19 CAR T Cells for Treatment of B-cell Malignancies caringcross.org ↗ For NHL complete responders, the one-year survival rate was 92.9%, with a median duration of response yet to be reached.
2021-11-29	Celularity Incorporated	Regulatory Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer celularity.com ↗
2021-11-09	Obsidian Therapeutics, Inc.	Results Obsidian Therapeutics to Present In Vivo Anti-TumorEfficacy Data from Novel Engineered cytoTIL15 Program at SITC 2021 obsidiantx.com ↗ cytoTIL15 TILs achieved significant tumor control in a human PDX model, which correlated with increased TIL accumulation in secondary lymphoid organs.
2021-10-18	Vertex Pharmaceuticals Incorporated	Results Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes vrtx.com ↗ Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive Day 90 data for the first patient from the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D).
2021-10-07	Allogene Therapeutics	Regulatory Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial allogene.com ↗ the U.S. Food and Drug Administration (FDA) has placed a hold on the Company’s AlloCAR T clinical trials.
2021-10-01	Kite, A Gilead Company	Regulatory U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia kitepharma.com ↗ Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has granted approval for Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
2021-08-27	LyGenesis, Inc.	Results LyGenesis Announces Four Peer-Reviewed Publications on its Organ Regeneration Technology lygenesis.com ↗ In 100% of the animals the transplanted liver cells engrafted into the lymph nodes, proliferated, and formed ectopic mini-livers, which had the same structure and function as native liver tissue.
2021-07-19	BlueRock Therapeutics	Regulatory BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson’s Disease bluerocktx.com ↗ BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson’s disease (PD).
2021-07-19	Bayer	Regulatory BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson’s Disease bayer.com ↗ BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson’s disease (PD).
2021-04-10	Gracell Biotechnologies (Shanghai) Co., Ltd.	Results Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting gracellbio.com ↗ today presented updated long-term follow-up data on their TruUCAR-enabled allogeneic product candidate GC027 for the treatment of adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) in an e-poster presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting on April 10.
2021-04-07	BlueRock Therapeutics	Regulatory BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson’s Disease bluerocktx.com ↗ Health Canada has given permission to initiate “Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson’s Disease (PD).”
2021-03-31	NKGen Biotech, Inc.	Regulatory Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors nkgenbiotech.com ↗
2021-03-26	Bristol-Myers Squibb	Regulatory U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma bms.com ↗
2021-02-24	Fate Therapeutics	Results Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress fatetherapeutics.com ↗ The patient subsequently received a second, single dose of FT596, which resulted in a deepening response as evidenced by further decreases in both tumor size and metabolic activity.
2021-02-10	Gilead Sciences	Results Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma gilead.com ↗ Kite, a Gilead Company (Nasdaq: GILD), today announced findings from a new analysis of the ZUMA-1 trial of Yescarta ® (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma (LBCL).
2021-02-08	Angiocrine Bioscience	Results Results of an Open Label Dose Escalation Trial of AB-205 (E-CEL® cells) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) angiocrinebioscience.com ↗ AB-205 is an experimental engineered-cell therapy designed to accelerate regeneration of organs and eliminate or reduce SRRT.
2021-01-07	BlueRock Therapeutics	Regulatory BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson’s Disease bluerocktx.com ↗
2021-01-07	Bayer	Regulatory BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson’s Disease bayer.com ↗
2020-12-02	Celularity Incorporated	Results Celularity Announces Positive DMC Safety Review and Continuation of its Phase I/II CYNK-001-COVID-19 (CYNKCOVID) Study celularity.com ↗ The DMC confirmed the absence of dose-limiting toxicities and recommended to move forward with the trial.
2020-10-26	Mustang Bio, Inc.	Results Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer mustangbio.com ↗ We are encouraged by the initial data presented by City of Hope from the ongoing Phase 1 trial of Mustang’s CAR T cell therapy MB-105.
2020-04-30	ExCellThera inc.	Regulatory ExCellThera announces EMA orphan medicinal product designation for ECT-001 Cell Therapy as treatment in haematopoietic stem cell transplantation excellthera.com ↗ “We are extremely pleased that our lead technology, ECT-001 Cell Therapy, has been granted orphan medicinal product designation from the EMA as treatment in haematopoietic stem cell transplantation,” said Dr. Guy Sauvageau, CEO and founder of ExCellThera.
2020-04-28	Gracell Biotechnologies (Shanghai) Co., Ltd.	Results Gracell Reports Data of First-in-human Clinical Trial for Universal TruUCAR™ GC027 in Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Virtual Annual Meeting gracellbio.com ↗ The study of TruUCAR ™ GC027 in relapsed and refractory T-ALL reports early efficacy outcomes of five patients treated in this area of high unmet medical need.
2020-02-25	ExCellThera inc.	Results ExCellThera announces preliminary Phase 2 data of ECT-001 Cell Therapy in high-risk leukemia and myelodysplasia excellthera.com ↗ The preliminary data was presented at the 2020 Transplant and Cellular Therapy (TCT) Annual Meeting in Orlando, Florida, and demonstrates excellent leukemia free survival in patients with high-risk leukemia and myelodysplasia.
2020-01-30	Alaunos Therapeutics	Results Ziopharm Oncology Announces Recent Publications in Peer-Reviewed Scientific Journals alaunos.com ↗ Five-year progression-free survival and overall survival were 71% and 86%, respectively.
2019-12-09	Novartis Pharmaceuticals	Results Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting novartis.com ↗ Novartis today announced results from two analyses of real-world experience with Kymriah ® (tisagenlecleucel), the only CAR-T cell therapy approved in two distinct indications.
2019-12-09	Mustang Bio, Inc.	Results Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency mustangbio.com ↗ MB-107 preceded by low-dose busulfan conditioning continues to be well tolerated and results in development of functional immune system in newly diagnosed infants with XSCID
2019-12-08	Bristol-Myers Squibb	Results Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology (ASH) Annual Meeting bms.com ↗ Bristol-Myers Squibb Company (NYSE: BMY) today announced data from multiple studies evaluating lisocabtagene maraleucel (liso-cel), an investigational CD19-directed CAR T-cell therapy with a defined composition of purified CD8+ and CD4+ CAR T cells, were presented during the 2019 ASH Annual Meeting in Orlando, Fla.
2019-07-19	Immatics Biotechnologies GmbH	Results Immatics Presents First Cohort Data on the ACTolog® Personalized Multi-Target Cell Therapy Trial Demonstrating Safety and T-cell Persistence in Treated Cancer Patients immatics.com ↗ The main conclusions from the currently available data set (N=9 patients, immune data for N=7 patients) are:
2019-06-25	Glycostem Therapeutics BV	Regulatory Glycostem received GMP license for oNKord® glycostem.com ↗ 25th June 2019 - Glycostem Therapeutics BV today announced they have received GMP license for Glycostem’s proprietary closed production system used to manufacture their lead product, oNKord®, an off-the-shelf,allogeneic Natural Killer(NK) cell therapy.
2019-06-01	Kite, A Gilead Company	Results Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia kitepharma.com ↗ Kite, a Gilead Company (Nasdaq: GILD), today announced results from the completed Phase 1 of the ZUMA-3 study evaluating KTE-X19, an investigational CD19 chimeric antigen receptor T (CAR T) cell therapy.
2019-06-01	Gilead Sciences	Results Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia gilead.com ↗ Kite, a Gilead Company (Nasdaq: GILD), today announced results from the completed Phase 1 of the ZUMA-3 study evaluating KTE-X19, an investigational CD19 chimeric antigen receptor T (CAR T) cell therapy.
2019-05-07	Fate Therapeutics	Results Fate Therapeutics Reports First Quarter 2019 Financial Results and Highlights Operational Progress fatetherapeutics.com ↗ First-ever Patient Treated in U.S. with an iPSC-derived Cell Therapy Successfully Advances through Six-dose Treatment Course
2019-02-25	Marker Therapeutics, Inc.	Results Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019 markertherapeutics.com ↗
2019-02-20	Wugen, Inc.	Results WUGEN Presents New Data for Key CAR-T Platform at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR wugen.com ↗ Our preclinical data validate the use of allogeneic ‘off-the-shelf’ adoptive immunotherapy for the treatment of Sézary syndrome, bringing hope to an underserved patient population.
2018-12-03	Kite, A Gilead Company	Results Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia kitepharma.com ↗ With a median follow-up of 15.1 months (range 3.7 – 28.6 months) following a single infusion of KTE-X19, 69 percent of evaluable patients (n=25/36) achieved complete tumor remission, defined as complete remission (CR) or CR with incomplete hematological recovery (CRi).
2018-12-03	Gilead Sciences	Results Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia gilead.com ↗ With a median follow-up of 15.1 months (range 3.7 – 28.6 months) following a single infusion of KTE-X19, 69 percent of evaluable patients (n=25/36) achieved complete tumor remission, defined as complete remission (CR) or CR with incomplete hematological recovery (CRi).
2018-10-04	Brainstorm-Cell Therapeutics	Results BrainStorm Poster Receives Clinical Abstract Award at NEALS Conference brainstorm-cell.com ↗ The biomarker data demonstrated increases in miRNA 132 and miRNA 146a and statistically significant decreases in MCP-1, SDF-1, CHIT-1 and Caspase-3 levels in CSF following a single MSC-NTF cell transplantation in the NurOwn® Phase 2 trial.
2018-05-03	Capricor Inc.	Results Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal capricor.com ↗ The presentations show systemic delivery of allogeneic CDCs improve exercise capability in a mouse model of Duchenne muscular dystrophy and highlight the mechanisms of action in Capricor’s pipeline therapies to treat diseases of inflammation and fibrosis,
2018-04-19	Capricor Inc.	Results Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model capricor.com ↗ Capricor Therapeutics (NASDAQ:CAPR) today announced that researchers found that repeat dosing of the company’s proprietary cellular therapy yields an increase in exercise performance in a disease model of Duchenne muscular dystrophy, the mdx mouse.
2017-12-11	Kite, A Gilead Company	Results Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia kitepharma.com ↗ With a minimum of eight weeks of follow-up, 71 percent of ALL patients (n=17/24) who received a single infusion of KTE-C19 achieved complete tumor remission (complete remission (CR) or CR with incomplete hematological recovery).
2017-12-11	Gilead Sciences	Results Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia gilead.com ↗ With a minimum of eight weeks of follow-up, 71 percent of ALL patients (n=17/24) who received a single infusion of KTE-C19 achieved complete tumor remission (complete remission (CR) or CR with incomplete hematological recovery).
2017-12-10	Alaunos Therapeutics	Results ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting alaunos.com ↗ Data presented from first- and second-generation SB clinical trials demonstrate safety, tolerability, disease response, long-term survival, and persistence of infused CD19-specific CAR + T cells.
2017-11-10	CRISPR Therapeutics	Results CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting crisprtx.com ↗ Today at the SITC Annual Meeting, scientists from CRISPR presented encouraging data from our CD19 Allogeneic CAR-T development program including in vitro and in vivo data demonstrating potent anti-tumor activity.
2017-04-20	Atara Biotherapeutics	Results Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology (AAN) Annual Meeting 2017 atarabio.com ↗ Three of six patients, including two with SPMS and one with PPMS, experienced improvements in MS symptoms as measured by patient reported and objective clinical evaluations
2016-06-11	Fate Therapeutics	Results Fate Therapeutics Announces Preclinical Data from Immuno-Regulatory CD34+ Cell Therapy for Autoimmune Diseases fatetherapeutics.com ↗ Scientists from Fate Therapeutics and Boston Children's Hospital demonstrated that a single administration of programmed cells results in durable correction of type 1 diabetes in a well-established non-obese diabetic (NOD) mouse model.
2016-05-23	BioRestorative Therapies	Results BioRestorative Therapies Announces Promising Data to Advance its Program for the Treatment of Metabolic Disorders biorestorative.com ↗ The study showed how brown adipose-derived stem cells, that were differentiated step-wise to functional 3D brown adipocyte constructs, were loaded into an encapsulation device designed to be used as a cell-based therapeutic for treating metabolic disorders.
2016-05-16	Fate Therapeutics	Results Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy fatetherapeutics.com ↗ Scientists from Fate Therapeutics and the University of Minnesota demonstrated through in vivo and in vitro preclinical studies that Adaptive NK cells exhibit enhanced persistence and deliver potent anti-tumor activity alone and in combination with therapeutic monoclonal antibodies.
2016-01-11	Cynata Therapeutics Limited	Results Cynata CLI Study Published in Peer Reviewed Journal cynata.com ↗
2015-12-07	Alaunos Therapeutics	Results ZIOPHARM Announces Presentation of Data From CD19-Specific CAR+ T-Cell Therapy Programs at ASH Annual Meeting alaunos.com ↗ ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP ), a biopharmaceutical company focused on new cancer immunotherapies, today announced that results from its CD19-specific CAR T-cell therapy programs were presented at the 57 th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
2015-10-01	Gilead Sciences	Results Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers gilead.com ↗ The study also showed T cells engineered with HPV-16 E6 TCR selectively destroyed HPV-16 positive tumor cells.
2015-03-02	Atara Biotherapeutics	Regulatory FDA Grants Breakthrough Therapy Designation to Epstein-Barr Virus (EBV) Targeted T-Cells for Treatment of EBV-Associated Lymphoproliferative Disease atarabio.com ↗ We are very pleased that our collaboration partner, MSK, has received breakthrough therapy designation, and we look forward to continuing our collective work to further develop this promising approach.

All press releases naming this drug 164 releases

Date	Issuer	Release
Show all 164 releases opens the full record — a long page

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Cell Therapy	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02923609 ↗
Modality	Cell therapy	“transendocardial CD34+ cell therapy” NCT02923609 ↗
Route	Other	“Transendocardial delivery of cell suspension in the SC Group” NCT02923609 ↗